Stockreport

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

Verrica Pharmaceuticals Inc.  (VRCA) 
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am Check Earnings Report
PDF – Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reduc [Read more]